GS-441524: the FIP antiviral

GS-441524 blocks the replication of the mutated feline coronavirus and interrupts the inflammatory cascade of FIP. Cure rate: 93% in clinical practice.

How does GS-441524 work?

GS-441524 is a nucleoside analogue that inhibits the RNA-dependent RNA polymerase of the FIP virus. It is the precursor of a nucleoside triphosphate molecule that the cell activates: the virus takes it up while copying its genetic material, believing it to be a normal building block, and the copy stops there. It therefore acts as an alternative substrate and RNA chain terminator. Simply put: it penetrates infected cells and prevents the virus from replicating. Without viral replication, the cat's immune system can recover and clear the residual virus.

Unlike corticosteroids, which only treat the symptoms, GS-441524 attacks the cause of the disease directly.

Recommended dosing

Oral doses are higher than injectable ones because oral absorption is roughly 50%. Adjust the dose with every weight gain: failing to do so is the main cause of treatment failure.

Form of FIP Oral GS (mg/kg/day) Injectable SC GS (mg/kg/day) Duration
Wet FIP (effusive) 12–18 mg/kg 6–8 mg/kg 84 days
Dry FIP (non-effusive) 12–18 mg/kg 6–8 mg/kg 84 days
Ocular FIP 16 mg/kg 8 mg/kg 84 days
Neurological FIP min. 20 mg/kg (in 2 doses) min. 10 mg/kg per day 84+ days

If there is no expected response, increase by 2 mg/kg injectable or 4 mg/kg oral. The doses of the ISFM protocol (remdesivir) differ from those of injectable GS-441524: they are not interchangeable. See the full clinical guide for the detailed tables.

What to expect in the first days

The response to treatment usually appears within the first 24–72 hours. Overall improvement consolidates over the first 2–4 weeks.

24–48 h

The fever settles. It is one of the first signs of response.

7 days

Red blood cells normalise. In immune-mediated haemolytic anaemia, prednisolone (4 mg/kg) may be needed to halt the haemolysis.

15 days

Ascites disappears visibly. The abdomen reduces noticeably in size.

Week 4

On ultrasound only a minimal amount of residual fluid may remain.

2–4 wks

The cat returns to normal: appetite, energy and weight recovering.

Monitoring during treatment

Rigorous follow-up matters as much as the antiviral itself. The goal at the end of week 12 is a healthy cat, alert and active, with normalised blood values. Sustained weight gain is one of the most reliable indicators of good progress.

Daily and weekly follow-up

  • Rectal temperature
  • Body weight
  • Activity level and appetite
  • Clinical signs of the disease

Blood work: at the start and every 4 weeks

  • Complete blood count (CBC)
  • Biochemistry: total protein, albumin, globulins and the A:G ratio

Supportive care during treatment

Cats that are critical at the start may need stabilising with symptomatic care while the antiviral begins to work:

  • Intravenous fluids and electrolytes to relieve dehydration
  • Antibiotics if a secondary bacterial infection is suspected
  • Anti-inflammatories to reduce the acute inflammatory response
  • Blood transfusion: rarely necessary
DO NOT drain

Abdominal effusion should not be drained unless it presses on the chest and stops the cat breathing normally. The fluid will build up again, and repeated drainage causes protein and electrolyte imbalance.

DO drain

Pleural effusions must be drained so that the cat can breathe normally.

Treatment protocol

1
Confirm the diagnosis

Before starting, confirm FIP with full blood work and fluid analysis where possible.

2
Calculate the dose

Based on the exact weight of the cat and the form of FIP (standard vs neurological).

3
First 7 days

Monitor closely: appetite, energy, reduction of the effusion. The first signs of improvement usually appear here.

4
Blood work at 30 days

First control panel. Assess proteins, albumin/globulin and complete blood count.

5
Day 84, end of treatment

Last dose. Final blood work. Start of the 84-day observation period.

6
Day 168, cure

If the cat stays free of symptoms with normalised blood work, it is declared cured.

Relapses

Between 8% and 10% of treated cats relapse. Relapses tend to occur in the first 10 days after finishing the 84-day course, though they can happen at any point during the observation period.

96% success rate
after a relapse

What a relapse involves: a second full 84-day course at a significantly higher dose. Relapses are usually more aggressive than the initial episode.

Options in resistant cases: raise the GS-441524 dose and, if there is still no response, consider molnupiravir. Always under specialist veterinary supervision.

Ending the treatment

Deciding when to stop is one of the hardest calls in the whole process. There is no simple test that confirms a cure, and fear of relapse often leads to extending the protocol or pushing doses up.

Standard criterion for cure

12 weeks of treatment completed, plus 84 days free of symptoms afterwards with normalised blood work.

Cases that may be shortened

Young cats with uncomplicated abdominal wet FIP can reach remission in 8 weeks, although the standard protocol is 12.

Cases that need extending

Neurological or ocular FIP, cats with a slow response, or blood work that does not quite normalise may need more than 84 days of treatment or dose increases.

Known side effects

GS-441524 is generally well tolerated. The most common side effects are:

  • Pain or local swelling at the injection site (SC)
  • Occasional nausea with oral formulations
  • Transient rise in liver enzymes in some cats
  • Rarely: changes in appetite at the start of treatment

FAQ

Questions about GS-441524

Clear answers to the most common questions.

Does your cat have FIP?

Tell us your situation and we'll tell you where to start.